1887

Chapter 150 : Mechanisms of Resistance to Antiparasitic Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Mechanisms of Resistance to Antiparasitic Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch150-1.gif /docserver/preview/fulltext/10.1128/9781555817381/9781555817381.ch150-2.gif

Abstract:

Parasitic diseases rank among the most prevalent and severe diseases worldwide and yet their control relies heavily on a single tool: the drugs used for chemotherapy or prophylaxis. This dependence on drugs is compounded by the relative paucity of the current armamentarium of antiparasitic products and the selection of drug-resistant parasites. Mechanisms for true resistance are varied and include a decrease in drug accumulation within the parasite or modifications in parasite enzyme structure or metabolic pathways. However, various host factors modulate the clinical and parasitologic responses to drug treatment, and the observed responses do not necessarily reflect true parasite resistance or susceptibility. A selective review of drug resistance in five parasitic diseases (malaria, trichomoniasis, leishmaniasis, African trypanosomiasis, and schistosomiasis) will illustrate the existing problems and their potential solutions.

Citation: Evan Secor W, Le Bras J, Clain J. 2015. Mechanisms of Resistance to Antiparasitic Agents, p 2550-2562. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch150
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817381.mcm11.ch150
1. World Health Organization. 1993. A global strategy for malaria control. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2014. World malaria report 2013. World Health Organization, Geneva, Switzerland.
3. Talisuna AO,, Bloland P,, D’Alessandro U. 2004. History, dynamics and public health importance of malaria parasite resistance. Clin Microbiol Rev 17:235254.
4. Fitch CD. 1970. Plasmodium falciparum in owl monkeys: drug resistance and chloroquine binding capacity. Science 169:289290.
5. Verdier F,, Le Bras J,, Clavier F,, Hatin I,, Blayo MC. 1985. Chloroquine uptake by Plasmodium falciparum-infected human erythrocytes during in vitro culture and its relationship to chloroquine resistance. Antimicrob Agents Chemother 27:561564.
6. Ecker A,, Lehane AM,, Clain J,, Fidock DA. 2012. PfCRT and its role in antimalarial drug resistance. Trends Parasitol 28:504514.
7. Bray PG,, Mungthin M,, Ridley RG,, Ward SA. 1998. Access to hematin: the basis of chloroquine resistance. Mol Pharmacol 54:170179.
8. Martin SK,, Oduola AM,, Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899901.
9. Foote SJ,, Thompson JK,, Cowman AF,, Kemp DJ. 1989. Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell 57:921930.
10. Reed MB,, Saliba KJ,, Caruana SR,, Kirk K,, Cowman AF. 2000. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906909.
11. Andriantsoanirina V,, Ratsimbasoa A,, Bouchier C,, Tichit M,, Jahevitra M,, Rabearimanana S,, Raherinjafy R,, Mercereau-Puijalon O,, Durand R,, Ménard D. 2010. Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar. PLoS One 5:e13281. 10.1371/journal.pone.0013281
12. Su X,, Kirkman LA,, Fujioka H,, Wellems TE. 1997. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell 91:593603.
13. Fidock DA,, Nomura T,, Talley AK,, Cooper RA,, Dzekunov SM,, Ferdig MT,, Ursos LM,, Sidhu AB,, Naudé B,, Deitsch KW,, Su XZ,, Wootton JC,, Roepe PD,, Wellems TE. 2000. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 6:861871.
14. Djimdé A,, Doumbo OK,, Cortese JF,, Kayentao K,, Doumbo S,, Diourté Y,, Dicko A,, Su XZ,, Nomura T,, Fidock DA,, Wellems TE,, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Eng J Med 344:257263.
15. Wootton JC,, Feng X,, Ferdig MT,, Cooper RA,, Mu J,, Baruch DI,, Magill AJ,, Su XZ. 2002. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 418:320323.
16. Sidhu AB,, Verdier-Pinard D,, Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 298:210213.
17. Martin RE,, Marchetti RV,, Cowan AI,, Howitt SM,, Bröer S,, Kirk K. 2009. Chloroquine transport via the malaria parasite’s chloroquine resistance transporter. Science 325: 16801682.
18. Johnson DJ,, Fidock DA,, Mungthin M,, Lakshmanan V,, Sidhu AB,, Bray PG,, Ward SA. 2004. Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol Cell 15:867877.
19. Ariey F,, Fandeur T,, Durand R,, Randrianarivelojosia M,, Jambou R,, Legrand E,, Ekala MT,, Bouchier C,, Cojean S,, Duchemin JB,, Robert V,, Le Bras J,, Mercereau-Puijalon O. 2006. Invasion of Africa by a single pfcrt allele of South East Asian type. Malar J 5:34.
20. Kublin JG,, Cortese JF,, Njunju EM,, Mukadam RA,, Wirima JJ,, Kazembe PN,, Djimdé AA,, Kouriba B,, Taylor TE,, Plowe CV. 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187:18701875.
21. Djimdé A,, Doumbo OK,, Steketee RW,, Plowe CV. 2001. Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet 358:890891.
22. Holmgren G,, Gil JP,, Ferreira PM,, Veiga MI,, Obonyo CO,, Björkman A. 2006. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol 6:309314.
23. Price RN,, Uhlemann AC,, Brockman A,, McGready R,, Ashley E,, Phaipun L,, Patel R,, Laing K,, Looareesuwan S,, White NJ,, Nosten F,, Krishna S. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364:438447.
24. Sidhu AB,, Valderramos SG,, Fidock DA. 2005. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol 57:913926.
25. Sisowath C,, Strömberg J,, Mårtensson A,, Msellem M,, Obondo C,, Björkman A,, Gil JP. 2005. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 191:10141017.
26. Sidhu AB,, Uhlemann AC,, Valderramos SG,, Valderramos JC,, Krishna S,, Fidock DA. 2006. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 194:528535.
27. Sisowath C,, Petersen I,, Veiga MI,, Mårtensson A,, Premji Z,, Björkman A,, Fidock DA,, Gil JP. 2009. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 199:750757.
28. Dahlström S,, Ferreira PE,, Veiga MI,, Sedighi N,, Wiklund L,, Mårtensson A,, Färnert A,, Sisowath C,, Osório L,, Darban H,, Andersson B,, Kaneko A,, Conseil G,, Björkman A,, Gil JP. 2009. Plasmodium falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J Infect Dis 200:14561464.
29. Dahlström S,, Veiga MI,, Mårtensson A,, Björkman A,, Gil JP. 2009. Polymorphism in PfMRP1 (Plasmodium falciparum multidrug resistance protein 1) amino acid 1466 associated with resistance to sulfadoxine-pyrimethamine treatment. Antimicrob Agents Chemother 53:25532556.
30. Dondorp AM,, Nosten F,, Yi P,, Das D,, Phyo AP,, Tarning J,, Lwin KM,, Ariey F,, Hanpithakpong W,, Lee SJ,, Ringwald P,, Silamut K,, Imwong M,, Chotivanich K,, Lim P,, Herdman T,, An SS,, Yeung S,, Singhasivanon P,, Day NP,, Lindegardh N,, Socheat D,, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455467.
31. Carrara VI,, Lwin KM,, Phyo AP,, Ashley E,, Wiladphaingern J,, Sriprawat K,, Rijken M,, Boel M,, McGready R,, Proux S,, Chu C,, Singhasivanon P,, White N,, Nosten F. 2013. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999–2011: an observational study. PLoS Med 10:e1001398. 10.1371/journal.pmed.1001398
32. Phyo AP,, Nkhoma S,, Stepniewska K,, Ashley EA,, Nair S,, McGready R,, ler Moo C,, Al-Saai S,, Dondorp AM,, Lwin KM,, Singhasivanon P,, Day NP,, White NJ,, Anderson TJ,, Nosten F. 2012. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet 379:19601966.
33. K Cheeseman IH,, Miller BA,, Nair S,, Nkhoma S,, Tan A,, Tan JC,, Al Saai S,, Phyo AP,, Moo CL,, Lwin KM,, McGready R,, Ashley E,, Imwong M,, Stepniewska K,, Yi P,, Dondorp AM,, Mayxay M,, Newton PN,, White NJ,, Nosten F,, Ferdig MT,, Anderson TJ. 2012. A major genome region underlying artemisinin resistance in malaria. Science 336: 7982.
34. Takala-Harrison S,, Clark TG,, Jacob CG,, Cummings MP,, Miotto O,, Dondorp AM,, Fukuda MM,, Nosten F,, Noedl H,, Imwong M,, Bethell D,, Se Y,, Lon C,, Tyner SD,, Saunders DL,, Socheat D,, Ariey F,, Phyo AP,, Starzengruber P,, Fuehrer HP,, Swoboda P,, Stepniewska K,, Flegg J,, Arze C,, Cerqueira GC,, Silva JC,, Ricklefs SM,, Porcella SF,, Stephens RM,, Adams M,, Kenefic LJ,, Campino S,, Auburn S,, MacInnis B,, Kwiatkowski DP,, Su XZ,, White NJ,, Ringwald P,, Plowe CV. 2013. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci USA 110:240245.
35. Miotto O,, Almagro-Garcia J,, Manske M,, Macinnis B,, Campino S,, Rockett KA,, Amaratunga C,, Lim P,, Suon S,, Sreng S,, Anderson JM,, Duong S,, Nguon C,, Chuor CM,, Saunders D,, Se Y,, Lon C,, Fukuda MM,, Amenga-Etego L,, Hodgson AV,, Asoala V,, Imwong M,, Takala-Harrison S,, Nosten F,, Su XZ,, Ringwald P,, Ariey F,, Dolecek C,, Hien TT,, Boni MF,, Thai CQ,, Amambua-Ngwa A,, Conway DJ,, Djimdé AA,, Doumbo OK,, Zongo I,, Ouedraogo JB,, Alcock D,, Drury E,, Auburn S,, Koch O,, Sanders M,, Hubbart C,, Maslen G,, Ruano-Rubio V,, Jyothi D,, Miles A,, O’Brien J,, Gamble C,, Oyola SO,, Rayner JC,, Newbold CI,, Berriman M,, Spencer CC,, McVean G,, Day NP,, White NJ,, Bethell D,, Dondorp AM,, Plowe CV,, Fairhurst RM,, Kwiatkowski DP. 2013. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet 45:648655.
36. Ariey F,, Witkowski B,, Amaratunga C,, Beghain J,, Langlois AC,, Khim N,, Kim S,, Duru V,, Bouchier C,, Ma L,, Lim P,, Leang R,, Duong S,, Sreng S,, Suon S,, Chuor CM,, Bout DM,, Ménard S,, Rogers WO,, Genton B,, Fandeur T,, Miotto O,, Ringwald P,, Le Bras J,, Berry A,, Barale JC,, Fairhurst RM,, Benoit-Vical F,, Mercereau-Puijalon O,, Ménard D. 2014. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505:5055.
37. Gregson A,, Plowe CV. 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 57:117145.
38. Peterson DS,, Walliker D,, Wellems TE. 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85:91149118.
39. Sirawaraporn W,, Sathitkul T,, Sirawaraporn R,, Yuthavong Y,, Santi DV. 1997. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 94:11241129.
40. Lozovsky ER,, Chookajorn T,, Brown KM,, Imwong M,, Shaw PJ,, Kamchonwongpaisan S,, Neafsey DE,, Weinreich DM,, Hartl DL. 2009. Stepwise acquisition of pyrimethamine resistance in the malaria parasite. Proc Natl Acad Sci USA 106:1202512030.
41. Cortese JF,, Caraballo A,, Contreras CE,, Plowe CV. 2002. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186: 9991006.
42. Plowe CV,, Cortese JF,, Djimde A,, Nwanyanwu OC,, Watkins WM,, Winstanley PA,, Estrada-Franco JG,, Mollinedo RE,, Avila JC,, Cespedes JL,, Carter D,, Doumbo OK. 1997. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 176:15901596.
43. Roper C,, Pearce R,, Nair S,, Sharp B,, Nosten F,, Anderson T. 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science 305:1124.
44. Maïga O,, Djimdé AA,, Hubert V,, Renard E,, Aubouy A,, Kironde F,, Nsimba B,, Koram K,, Doumbo OK,, Le Bras J,, Clain J. 2007. A shared Asian origin of the triple mutant dhfr allele in P. falciparum from sites across Africa. J Infect Dis. 196:165172.
45. Wang P,, Read M,, Sims PF,, Hyde JE. 1997. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol Microbiol 23:979986.
46. Triglia T,, Wang P,, Sims PF,, Hyde JE,, Cowman AF. 1998. Allellic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J 17: 38073815.
47. Pearce RJ,, Pota H,, Evehe MS,, el-H,, Mombo-Ngoma G,, Malisa AL,, Ord R,, Inojosa W,, Matondo A,, Diallo DA,, Mbacham W,, van den BroekIV,, Swarthout TD,, Getachew A,, Dejene S,, Grobusch MP,, Njie F,, Dunyo S,, Kweku M,, Owusu-Agyei S,, Chandramohan D,, Bonnet M,, Guthmann JP,, Clarke S,, Barnes KI,, Streat E,, Katokele ST,, Uusiku P,, Agboghoroma CO,, Elegba OY,, Cissé B,, A-Elbasit IE,, Giha HA,, Kachur SP,, Lynch C,, Rwakimari JB,, Chanda P,, Hawela M,, Sharp B,, Naidoo I,, Roper C. 2009. Multiple origins and regional dispersal of resistant dhps in African Plasmodium falciparum malaria. PLoS Med 6:e1000055. 10.1371/journal.pmed.1000055
48. Kublin JG,, Dzinjalamala FK,, Kamwendo DD,, Malkin EM,, Cortese JF,, Martino LM,, Mukadam RA,, Rogerson SJ,, Lescano AG,, Molyneux ME,, Winstanley PA,, Chimpeni P,, Taylor TE,, Plowe CV. 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185:380388.
49. Basco LK,, Ringwald P. 2000. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am J Trop Med Hyg 62:271276.
50. Srivastava IK,, Morrisey JM,, Darrouzet E,, Daldal F,, Vaidya AB. 1999. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 33:704711.
51. Srivastava IK,, Vaidya AB. 1999. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 43:13341339.
52. Looareesuwan SC,, Viravan C,, Webster HK,, Kyle DE,, Hutchinson DB,, Canfield CJ. 1996. Clinical studies on atovaquone, alone or in association with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 54:6266.
53. Kessl JJ,, Ha KH,, Merritt AK,, Lange BB,, Hill P,, Meunier B,, Meshnick SR,, Trumpower BL. 2005. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J Biol Chem 280:1714217148.
54. Musset L,, Bouchaud O,, Matheron S,, Massias L,, Le Bras J. 2006. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect 8:25992604.
55. Fivelman QL,, Adagu IS,, Warhurst DC. 2004. Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 48:40974102.
56. Musset L,, Pradines B,, Parzy D,, Durand R,, Bigot P,, Le Bras J. 2006. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 57:110115.
57. Musset L,, Le Bras J,, Clain J. 2007. Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquone-proguanil treatment. Mol Biol Evol 24:15821585.
58. Smoak BL,, DeFraites RF,, Magill AJ,, Kain KC,, Wellde BT. 1997. Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. Am J Trop Med Hyg 56:231234.
59. Bennett JW,, Pybus BS,, Yadava A,, Tosh D,, Sousa JC,, McCarthy WF,, Deye G,, Melendez V,, Ockenhouse CF. 2013. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 369:13811382.
60. Nomura T,, Carlton JM,, Baird JK,, del Portillo HA,, Fryauff DJ,, Rathore D,, Fidock DA,, Su X,, Collins WE,, McCutchan TF,, Wootton JC,, Wellems TE. 2001. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J Infect Dis 183:16531661.
61. Brega S,, Meslin B,, de Montbrison F,, Severini C,, Gradoni L,, Udomsangpetch R,, Sutanto I,, Peyron F,, Picot S. 2005. Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J Infect Dis 191:272277.
62. Hastings MD,, Porter KM,, Maguire JD,, Susanti I,, Kania W,, Bangs MJ,, Sibley CH,, Baird JK. 2004. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis 189:744750.
63. Korsinczky M,, Fischer K,, Chen N,, Baker J,, Rieckmann K,, Cheng Q. 2004. Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother 48:22142222.
64. World Health Organization. 2011. Prevalence and incidence of selected sexually transmitted infections, Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: methods and results used by WHO to generate 2005 estimates. http://whqlibdoc.who.int/publi cations/2011/9789241502450_eng.pdf.
65. Mann JR,, McDermott S,, Gill T. 2010. Sexually transmitted infection is associated with increased risk of preterm birth in South Carolina women insured by Medicaid. J Matern Fetal Neonatal Med 23:563568.
66. Van Der Pol B,, Kwok C,, Pierre-Louis B,, Rinaldi A,, Salata RA,, Chen PL,, van de Wijgert J,, Mmiro F,, Mugerwa R,, Chipato T,, Morrison CS. 2008. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis 197:548554.
67. Kissinger P,, Amedee A,, Clark RA,, Dumestre J,, Theall KP,, Myers L,, Hagensee ME,, Farley TA,, Martin DH. 2009. Trichomonas vaginalis treatment reduces vaginal HIV-1 shedding. Sex Transm Dis 36:1116.
68. McClelland RS. 2008. Trichomonas vaginalis infection: can we afford to do nothing? J Infect Dis 197:487489.
69. van der Pol B. 2007. Trichomonas vaginalis infection: the most prevalent nonviral sexually transmitted infection receives the least public health attention. Clin Infect Dis 44:2325.
70. Crowell AL,, Sanders-Lewis KA,, Secor WE. 2003. In vitro metronidazole and tinidazole activities against metronidazole-resistant strains of Trichomonas vaginalis. Antimicrob Agents Chemother 47:14071409.
71. Workowski KA,, Berman SM. 2011. Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 53(Suppl 3):S59S63.
72. Bosserman EA,, Helms DJ,, Mosure DJ,, Secor WE,, Workowski KA. 2011. Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure. Sex Transm Dis 38:983987.
73. Snipes LJ,, Gamard PM,, Narcisi EM,, Beard CB,, Lehmann T,, Secor WE. 2000. Molecular epidemiology of metronidazole resistance in a population of Trichomonas vaginalis clinical isolates. J Clin Microbiol 38:30043009.
74. Conrad MD,, Gorman AW,, Schillinger JA,, Fiori PL,, Arroyo R,, Malla N,, Dubey ML,, Gonzalez J,, Blank S,, Secor WE,, Carlton JM. 2012. Extensive genetic diversity, unique population structure and evidence of genetic exchange in the sexually transmitted parasite Trichomonas vaginalis. PLoS Negl Trop Dis 6:e1573. 10.1371/journal.pntd. 0001573
75. Paulish-Miller TE,, Augostini P,, Schuyler JA,, Smith WL,, Mordechai E,, Adelson ME,, Gygax SE,, Secor WE,, Hilbert DW. 2014. Trichomonas vaginalis metronidazole resistance is associated with single nucleotide polymorphisms in the nitroreductase genes ntr4Tv and ntr6Tv. Antimicrob Agents Chemother 58:29382943.
76. Kirkcaldy RD,, Augostini P,, Asbel LE,, Bernstein KT,, Kerani RP,, Mettenbrink CJ,, Pathela P,, Schwebke JR,, Secor WE,, Workowski KA,, Davis D,, Braxton J,, Weinstock HS. 2012. Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009–2010. Emerg Infect Dis 18:939943.
77. Land KM,, Delgadillo MG,, Johnson PJ. 2002. In vivo expression of ferredoxin in a drug resistant trichomonad increases metronidazole susceptibility. Mol Biochem Parasitol 121:153157.
78. Rasoloson D,, Vanácová S,, Tomková E,, Rázga J,, Hrdy I,, Tachez J,, Kulda J. 2002. Mechanisms of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology 148:24672477.
79. Hrd I,, Cammack R,, Stopka P,, Kulda J,, Tachezy J. 2005. Alternative pathway of metronidazole activation in Trichomonas vaginalis hydrogenosomes. Antimicrob Agents Chemother 49:50335036.
80. Wright JM,, Webb RI,, O’Donoghue P,, Upcroft P,, Upcroft JA. 2010. Hydrogenosomes of laboratory-induced metronidazole-resistant Trichomonas vaginalis lines are downsized while those from clinically metronidazole-resistant isolates are not. J Eukaryot Microbiol 57:171176.
81. Mead JR,, Fernadez M,, Romagnoli PA,, Secor WE. 2006. Use of Trichomonas vaginalis clinical isolates to evaluate correlation of gene expression and metronidazole resistance. J Parasitol 92:196199.
82. Leitsch D,, Kolarich D,, Binder M,, Stadlmann J,, Altmann F,, Duchêne M. 2009. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol 72:518536.
83. Leitsch D,, Kolarich D,, Duchêne M. 2010. The flavin inhibitor diphenyleneiodonium renders Trichomonas vaginalis resistant to metronidazole, inhibits thioredoxin reductase and flavin reductase, and shuts off hydrogenosomal enzymatic pathways. Mol Biochem Parasitol 171:1724.
84. Xiao JC,, Xie LF,, Fang SL,, Gao MY,, Zhu Y,, Song LY,, Zhong HM,, Lun ZR. 2006. Symbiosis of Mycoplasma hominis in Trichomonas vaginalis may link metronidazole resistance in vitro. Parasitol Res 100:123130.
85. Butler SE,, Augostini P,, Secor WE. 2010. Mycoplasma hominis infection of Trichomonas vaginalis is not associated with metronidazole-resistant trichomoniasis in clinical isolates from the United States. Parasitol Res 107:10231027.
86. Helms DJ,, Mosure DJ,, Secor WE,, Workowski KA. 2008. Management of Trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 198:370.e17.
87. Goodhew EB,, Secor WE. 2013. Drug library screening against metronidazole-sensitive and metronidazole-resistant Trichomonas vaginalis isolates. Sex Transm Infect 89:479484.
88. Waters LJ,, Dave SS,, Deayton JR,, French PD. 2005. Recalcitrant Trichomonas vaginalis infection—a case series. Int J STD AIDS 16:505509.
89. Muzny C,, Barnes A,, Mena L. 2012. Symptomatic Trichomonas vaginalis infection in the setting of severe nitroimidazole allergy: successful treatment with boric acid. Sex Health 9:389391.
90. Jarvis JN,, Lockwood DN. 2013. Clinical aspects of visceral leishmaniasis in HIV infection. Curr Opin Infect Dis 26:19.
91. Cota GF,, de Sousa MR,, Fereguetti TO,, Rabello A. 2013. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 7:e2195. 10 .1371/journal.pntd.0002195
92. Mishra J,, Saxena A,, Singh S. 2007. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 14:11531169.
93. Rijal S,, Yardley V,, Chappuis F,, Decuypere S,, Khanal B,, Singh R,, Boelaert M,, De Doncker S,, Croft S,, Dujardin JC. 2007. Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect 9: 529535.
94. Aït-Oudhia K,, Gazanion E,, Vergnes B,, Oury B,, Sereno D. 2011. Leishmania antimony resistance: what we know what we can learn from the field. Parasitol Res 109:12251232.
95. Torres DC,, Ribeiro-Alves M,, Romero GA,, Dávila AM,, Cupolillo E. 2013. Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil. Acta Trop 126: 132141.
96. Berg M,, Mannaert A,, Vanaerschot M,, Van Der Auwera G,, Dujardin JC. 2013. (Post-) Genomic approaches to tackle drug resistance in Leishmania. Parasitology 140: 14921505.
97. Natera S,, Machuca C,, Padrón-Nieves M,, Romero A,, Díaz E,, Ponte-Sucre A. 2007. Leishmania spp.: proficiency of drug-resistant parasites. Int J Antimicrob Agents 29:637642.
98. Croft SL,, Sundar S,, Fairlamb AH. 2006. Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111126.
99. Sundar S. 2001. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6:849854.
100. Adaui V,, Maes I,, Huyse T,, Van den Broeck F,, Talledo M,, Kuhls K,, De Doncker S,, Maes L,, Llanos-Cuentas A,, Schönian G,, Arevalo J,, Dujardin JC. 2011. Multilocus genotyping reveals a polyphyletic pattern among naturally antimony-resistant Leishmania braziliensis isolates from Peru. Infect Genet Evol 11:18731880.
101. Decuypere S,, Vanaerschot M,, Brunker K,, Imamura H,, Müller S,, Khanal B,, Rijal S,, Dujardin JC,, Coombs GH. 2012. Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background. PLoS Negl Trop Dis 6:e1514. 10.1371/journal.pntd .0001514
102. do Monte-Neto RL,, Coelho AC,, Raymond F,, Légaré D,, Corbeil J,, Melo MN,, Frézard F,, Ouellette M. 2011. Gene expression profiling and molecular characterization of antimony resistance in Leishmania amazonensis. PLoS Negl Trop Dis 5:e1167. 10.1371/journal.pntd.0001167
103. Rai S,, Bhaskar,, Goel SK,, Nath Dwivedi U,, Sundar S,, Goyal N. 2013. Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One 8:e74862. 10.1371/journal.pone. 0074862
104. Mukherjee A,, Boisvert S,, do Monte-Neto RL,, Coelho AC,, Raymond F,, Mukhopadhyay R,, Corbeil J,, Ouellette M. 2013. Telomeric gene deletion and intrachromosomal amplification in antimony-resistant Leishmania. Mol Microbiol 88:189202.
105. Mittal MK,, Rai S,, Ashutosh,, Ravinder,, Gupta S,, Sundar S,, Goyal N. 2007. Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg 76:681688.
106. Mukherjee A,, Padmanabhan PK,, Singh S,, Roy G,, Girard I,, Chatterjee M,, Ouellette M,, Madhubala R. 2007. Role of ABC transporter MRPA, γ-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother 59:204211.
107. Walker J,, Gongora R,, Vasquez JJ,, Drummelsmith J,, Burchmore R,, Roy G,, Ouellette M,, Gomez MA,, Saravia NG. 2012. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol 183:166176.
108. Mukhopadhyay R,, Mukherjee S,, Mukherjee B,, Naskar K,, Mondal D,, Decuypere S,, Ostyn B,, Prajapati VK,, Sundar S,, Dujardin JC,, Roy S. 2011. Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol 41:13111321.
109. Manzano JI,, García-Hernández R,, Castanys S,, Gamarro F. 2013. A new ABC half-transporter in Leishmania major is involved in resistance to antimony. Antimicrob Agents Chemother 57:37193730.
110. Matrangolo FS,, Liarte DB,, Andrade LC,, de Melo MF,, Andrade JM,, Ferreira RF,, Santiago AS,, Pirovani CP,, Silva-Pereira RA,, Murta SM. 2013. Comparative proteomic analysis of antimony-resistant and -susceptible Leishmania braziliensis and Leishmania infantum chagasi lines. Mol Biochem Parasitol 190:6375.
111. Berg M,, Vanaerschot M,, Jankevics A,, Cuypers B,, Maes I,, Mukherjee S,, Khanal B,, Rijal S,, Roy S,, Opperdoes F,, Breitling R,, Dujardin JC. 2013. Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure. Mol Microbiol 90:428442.
112. Bhandari V,, Kulshrestha A,, Deep DK,, Stark O,, Prajapati VK,, Ramesh V,, Sundar S,, Schonian G,, Dujardin JC,, Salotra P. 2012. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis 6:e1657. 10.1371/journal.pntd. 0001657
113. Sundar S,, Olliaro PL. 2007. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3:733740.
114. Rijal S,, Ostyn B,, Uranw S,, Rai K,, Bhattarai NR,, Dorlo TP,, Beijnen JH,, Vanaerschot M,, Decuypere S,, Dhakal SS,, Das ML,, Karki P,, Singh R,, Boelaert M,, Dujardin JC. 2013. Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56:15301538.
115. Kumar D,, Kulshrestha A,, Singh R,, Salotra P. 2009. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother 53:835838.
116. Sánchez-Cañete MP,, Carvalho L,, Pérez-Victoria FJ,, Gamarro F,, Castanys S. 2009. Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug. Antimicrob Agents Chemother 53:13051313.
117. Pérez-Victoria JM,, Bavchvarov BI,, Torrecillas IR,, Martínez-García M,, López-Martín C,, Campillo M,, Castanys S,, Gamarro F. 2011. Sitamaquine overcomes ABC-mediated resistance to miltefosine and antimony in Leishmania. Antimicrob Agents Chemother 55:38383854.
118. Rai K,, Cuypers B,, Bhattarai NR,, Uranw S,, Berg M,, Ostyn B,, Dujardin JC,, Rijal S,, Vanaerschot M. 2013. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. MBio 4:e0061113.
119. Bern C,, Adler-Moore J,, Berenguer J,, Boelaert M,, den Boer M,, Davidson RN,, Figueras C,, Gradoni L,, Kafetzis DA,, Ritmeijer K,, Rosenthal E,, Royce C,, Russo R,, Sundar S,, Alvar J. 2006. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 43:917924.
120. Mueller M,, Ritmeijer K,, Balasegaram M,, Koummuki Y,, Santana MR,, Davidson R. 2007. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 101:1924.
121. Lachaud L,, Bourgeois N,, Plourde M,, Leprohon P,, Bastien P,, Ouellette M. 2009. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis 48:e1622.
122. Purkait B,, Kumar A,, Nandi N,, Sardar AH,, Das S,, Kumar S,, Pandey K,, Ravidas V,, Kumar M,, De T,, Singh D,, Das P. 2012. Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother 56:10311041.
123. Rijal S,, Bhandari S,, Koirala S,, Singh R,, Khanal B,, Loutan L,, Dujardin JC,, Boelaert M,, Chappuis F. 2010. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal. Trans R. Soc Trop Med Hyg 104:225229.
124. Mukherjee B,, Mukhopadhyay R,, Bannerjee B,, Chowdhury S,, Mukherjee S,, Naskar K,, Allam US,, Chakravortty D,, Sundar S,, Dujardin JC,, Roy S. 2013. Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci USA 110:E575582.
125. Gautam S,, Kumar R,, Maurya R,, Nylén S,, Ansari N,, Rai M,, Sundar S,, Sacks D. 2011. IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis 204: 11341137.
126. Brun R,, Blum J,, Chappuis F,, Burri C. 2010. Human African trypanosomiasis. Lancet 375:148159.
127. Baker N,, de Koning HP,, Mäser P,, Horn D. 2013. Drug resistance in African trypanosomiasis: the melarsoprol and pentamidine story. Trends Parasitol 29:110118.
128. Barrett MP,, Vincent IM,, Burchmore RJ,, Kazibwe AJ,, Matovu E. 2011. Drug resistance in human African trypanosomiasis. Future Microbiol 6:10371047.
129. Delespaux V,, de Koning HP. 2007. Drugs and drug resistance in African trypanosomiasis. Drug Resist Updat 10:3050.
130. Stewart ML,, Burchmore RJ,, Clucas C,, Hertz-Fowler C,, Brooks K,, Tait A,, Macleod A,, Turner CM,, De Koning HP,, Wong PE,, Barrett MP. 2010. Multiple genetic mechanisms lead to loss of functional TbAT1 expression in drug-resistant trypanosomes. Eukaryot Cell 9:336343.
131. Nerima B,, Matovu E,, Lubega GW,, Enyaru JC. 2007. Detection of mutant P2 adenosine transporter (TbAT1) gene in Trypanosoma brucei gambiense isolates from northwest Uganda using allele-specific polymerase chain reaction. Trop Med Int Health 12:13611368.
132. de Koning HP. 2008. Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes. Trends Parasitol 24:345349.
133. Baker N,, Glover L,, Munday JC,, Aguinaga Andrés D,, Barrett MP,, de Koning HP,, Horn D. 2012. Aquaglyceroporin 2 controls susceptibility to melarsoprol and pentamidine in African trypanosomes. Proc Natl Acad Sci USA 109:1099611001.
134. Munday JC,, Eze AA,, Baker N,, Glover L,, Clucas C,, Aguinaga Andrés D,, Natto MJ,, Teka IA,, McDonald J,, Lee RS,, Graf FE,, Ludin P,, Burchmore RJ,, Turner CM,, Tait A,, Macleod A,, Mäser P,, Barrett MP,, Horn D,, De Koning HP. 2013. Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. J Antimicrob Chemother 69:651663.
135. Lüscher A,, Nerima B,, Mäser P. 2006. Combined contributions of TbAT1 and TbMRPA to drug resistance in Trypanosoma brucei. Mol Biochem Parasitol 150:364366.
136. Robays J,, Nyamowala G,, Sese C,, Betu Ku Mesu Kande V,, Lutumba P,, Van der Veken W,, Boelaert M. 2008. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Emerg Infect Dis 14:966967.
137. Vincent IM,, Creek D,, Watson DG,, Kamleh MA,, Woods DJ,, Wong PE,, Burchmore RJ,, Barrett MP. 2010. A molecular mechanism for eflornithine resistance in African trypanosomes. PLoS Pathog 6:e1001204. 10.1371/journal.ppat.1001204
138. Sokolova AY,, Wyllie S,, Patterson S,, Oza SL,, Read KD,, Fairlamb AH. 2010. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother 54:28932900.
139. Utzinger J,, N’Goran EK,, N’Dri A,, Lengeler C,, Tanner M. 2000. Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Trop Med Intl Health 5:771778.
140. Montresor A. 2011. Cure rate is not a valid indicator for assessing drug efficacy and impact of preventive chemotherapy interventions against schistosomiasis and soil-transmitted helminthiasis. Trans R Soc Trop Med Hyg 105:361363.
141. Tchuem Tchuenté LA,, Momo SC,, Stothard JR,, Rollinson D. 2013. Efficacy of praziquantel and reinfection patterns in single and mixed infection foci for intestinal and urogenital schistosomiasis in Cameroon. Acta Trop 128:275283.
142. Reta B,, Erko B. 2013. Efficacy and side effects of praziquantel in the treatment for Schistosoma mansoni infection in school children in Senbete Town, northeastern Ethiopia. Trop Med Int Health 18:13381343.
143. Tukahebwa EM,, Vennervald BJ,, Nuwaha F,, Kabatereine NB,, Magnussen P. 2013. Comparative efficacy of one versus two doses of praziquantel on cure rate of Schistosoma mansoni infection and re-infection in Mayuge District, Uganda. Trans R Soc Trop Med Hyg 107:397404.
144. King CH,, Olbrych SK,, Soon M,, Singer ME,, Carter J,, Colley DG. 2011. Utility of repeated praziquantel dosing in the treatment of schistosomiasis in high-risk communities in Africa: a systematic review. PLoS Negl Trop Dis 5:e1321. 10.1371/journal.pntd.0001321
145. Garba A,, Lamine MS,, Barkiré N,, Djibo A,, Sofo B,, Gouvras AN,, Labbo R,, Sebangou H,, Webster JP,, Fenwick A,, Utzinger J. 2013. Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger. Acta Trop 128:334344.
146. Webster BL,, Diaw OT,, Seye MM,, Faye DS,, Stothard JR,, Sousa-Figueiredo JC,, Rollinson D. 2013. Praziquantel treatment of school children from single and mixed infection foci of intestinal and urogenital schistosomiasis along the Senegal River Basin: monitoring treatment success and re-infection patterns. Acta Trop 128:292302.
147. Melman SD,, Steinauer ML,, Cunningham C,, Kubatko LS,, Mwangi IN,, Wynn NB,, Mutuku MW,, Karanja DM,, Colley DG,, Black CL,, Secor WE,, Mkoji GM,, Loker ES. 2009. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3:e504. 10.1371/journal.pntd .0000504
148. Ismail M,, Metwally A,, Farghaly A,, Bruce J,, Tao LF,, Bennett JL. 1996. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg 55:214218.
149. Lamberton PH,, Hogan SC,, Kabatereine NB,, Fenwick A,, Webster JP. 2010. In vitro praziquantel test capable of detecting reduced in vivo efficacy in Schistosoma mansoni human infections. Am J Trop Med Hyg 83:13401347.
150. Black CL,, Steinauer ML,, Mwinzi PN,, Secor W,, Karanja DM,, Colley DG. 2009. Impact of intense, longitudinal retreatment with praziquantel on cure rates of Schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya. Trop Med Int Health 14:450457.
151. Guidi A,, Andolina C,, Makame Ame S,, Albonico M,, Cioli D,, Juma Haji H. 2010. Praziquantel efficacy and long-term appraisal of schistosomiasis control in Pemba Island. Trop Med Int Health 15:614618.
152. Seto EY,, Wong BK,, Lu D,, Zhong B. 2011. Human schistosomiasis resistance to praziquantel in China: should we be worried? Am J Trop Med Hyg 85:7482.
153. Coeli R,, Baba EH,, Araujo N,, Coelho PM,, Oliveira G. 2013. Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections. PLoS Negl Trop Dis 7:e2596. 10.1371/journalpntd.0002596
154. Norton AJ,, Gower CM,, Lamberton PH,, Webster BL,, Lwambo NJ,, Blair L,, Fenwick A,, Webster JP. 2010. Genetic consequences of mass human chemotherapy for Schistosoma mansoni: population structure pre- and post-praziquantel treatment in Tanzania. Am J Trop Med Hyg 83:951957.
155. Blanton RE,, Blank WA,, Costa JM,, Carmo TM,, Reis EA,, Silva LK,, Barbosa LM,, Test MR,, Reis MG. 2011. Schistosoma mansoni population structure and persistence after praziquantel treatment in two villages of Bahia, Brazil. Int J Parasitol 41:10931099.
156. Huyse T,, Van den Broeck F,, Jombart T,, Webster BL,, Diaw O,, Volckaert FA,, Balloux F,, Rollinson D,, Polman K. 2013. Regular treatments of praziquantel do not impact on the genetic make-up of Schistosoma mansoni in Northern Senegal. Infect Genet Evol 18:100105.
157. Doenhoff MJ,, Cioli D,, Utzinger J. 2008. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21:659667.
158. Nogi T,, Zhang D,, Chan JD,, Marchant JS. 2009. A novel biological activity of praziquantel requiring voltage-operated Ca2+ channel β subunits: subversion of flatworm regenerative polarity. PLoS Negl Trop Dis 3:e464. 10. 1371/journal.pntd.0000464
159. Greenberg RM. 2013. New approaches for understanding mechanisms of drug resistance in schistosomes. Parasitology 140:15341546.
160. Valle C,, Troiani AR,, Festucci A,, Pica-Mattoccia L,, Liberti P,, Wolstenholme A,, Francklow K,, Doenhoff MJ,, Cioli D. 2003. Sequence and level of endogenous expression of calcium channel β subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel. Mol Biochem Parasitol 130:111115.
161. Pica-Mattoccia L,, Orsini T,, Basso A,, Festucci A,, Liberti P,, Guidi A,, Marcatto-Maggi AL,, Nobre-Santana S,, Troiani AR,, Cioli D,, Valle C. 2008. Schistosoma mansoni: lack of correlation between praziquantel-induced intra-worm calcium influx and parasite death. Exp Parasitol 119:332335.
162. Angelucci F,, Basso A,, Bellelli A,, Brunori M,, Pica Mattoccia L,, Valle C. 2007. The anti-schistosomal drug praziquantel is an adenosine antagonist. Parasitology 134:12151221.
163. Gnanasekar M,, Salunkhe AM,, Mallia AK,, He YX,, Kalyanasundaram R. 2009. Praziquantel affects the regulatory myosin light chain of Schistosoma mansoni. Antimicrob Agents Chemother 53:10541060.
164. Messerli SM,, Kasinathan RS,, Morgan W,, Spranger S,, Greenberg RM. 2009. Schistosoma mansoni P-glycoprotein levels increase in response to praziquantel exposure and correlate with reduced praziquantel susceptibility. Mol Biochem Parasitol 167:5459.
165. Greenberg RM. 2013. ABC multidrug transporters in schistosomes and other parasitic flatworms. Parasitol Int 62:647653.
166. Pica-Mattoccia L,, Doenhoff MJ,, Valle C,, Basso A,, Troiani AR,, Liberti P,, Festucci A,, Guidi A,, Cioli D. 2009. Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni. Acta Trop 111:8285.
167. Kasinathan RS,, Morgan WM,, Greenberg RM. 2010. Schistosoma mansoni express higher levels of multidrug resistance-associated protein 1 (SmMRP1) in juvenile worms and in response to praziquantel. Mol Biochem Parasitol 173:2531.
168. Hines-Kay J,, Cupit PM,, Sanchez MC,, Rosenberg GH,, Hanelt B,, Cunningham C. 2012. Transcriptional analysis of Schistosoma mansoni treated with praziquantel in vitro. Mol Biochem Parasitol 186:8794.
169. Doenhoff MJ,, Hagan P,, Cioli D,, Southgate V,, Pica-Mattoccia L,, Botros S,, Coles G,, Tchuem Tchuenté LA,, Mbaye A,, Engels D. 2009. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 136:18251835.
170. Caffrey CR,, Secor WE. 2011. Schistosomiasis: from drug deployment to drug development. Curr Opin Infect Dis 24:410417.
171. Secor WE,, Meites E,, Starr MC,, Workowski KA. 2014. Neglected parasitic diseases in the United States: Trichomoniasis. Am J Trop Med Hyg 90:800804.

Tables

Generic image for table
TABLE 1

Summary of proposed mechanisms of resistance to selected antiparasitic drugs

Citation: Evan Secor W, Le Bras J, Clain J. 2015. Mechanisms of Resistance to Antiparasitic Agents, p 2550-2562. In Jorgensen J, Pfaller M, Carroll K, Funke G, Landry M, Richter S, Warnock D (ed), Manual of Clinical Microbiology, Eleventh Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817381.ch150

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error